Legal & General Group Plc lifted its position in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) by 9.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 44,756 shares of the biopharmaceutical company’s stock after acquiring an additional 3,701 shares during the period. Legal & General Group Plc owned 0.10% of Sucampo Pharmaceuticals worth $470,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SCMP. NEA Management Company LLC acquired a new position in shares of Sucampo Pharmaceuticals in the 2nd quarter valued at $13,214,000. Rubric Capital Management LP acquired a new position in shares of Sucampo Pharmaceuticals in the 2nd quarter valued at $6,068,000. Vanguard Group Inc. increased its position in shares of Sucampo Pharmaceuticals by 48.9% in the 1st quarter. Vanguard Group Inc. now owns 1,456,787 shares of the biopharmaceutical company’s stock valued at $16,024,000 after acquiring an additional 478,226 shares during the period. Royce & Associates LP increased its position in shares of Sucampo Pharmaceuticals by 24.6% in the 1st quarter. Royce & Associates LP now owns 974,023 shares of the biopharmaceutical company’s stock valued at $10,714,000 after acquiring an additional 192,000 shares during the period. Finally, Bank of New York Mellon Corp increased its position in shares of Sucampo Pharmaceuticals by 107.3% in the 1st quarter. Bank of New York Mellon Corp now owns 367,691 shares of the biopharmaceutical company’s stock valued at $4,044,000 after acquiring an additional 190,292 shares during the period. 55.44% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms recently issued reports on SCMP. Zacks Investment Research raised Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday. Mizuho downgraded Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the company from $14.00 to $12.00 in a research report on Tuesday. Leerink Swann began coverage on Sucampo Pharmaceuticals in a research report on Monday, August 21st. They issued an “outperform” rating and a $15.00 target price on the stock. Maxim Group reissued a “buy” rating and issued a $23.00 target price (up from $21.00) on shares of Sucampo Pharmaceuticals in a research report on Tuesday, August 8th. Finally, BidaskClub downgraded Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 5th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Sucampo Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $17.86.

In other news, insider Jones W. Bryan purchased 4,700 shares of the company’s stock in a transaction dated Friday, August 4th. The shares were acquired at an average cost of $10.60 per share, for a total transaction of $49,820.00. Following the completion of the purchase, the insider now directly owns 4,700 shares in the company, valued at approximately $49,820. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of the business’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $12.00, for a total transaction of $12,000,000.00. The disclosure for this sale can be found here. Insiders own 4.13% of the company’s stock.

Shares of Sucampo Pharmaceuticals, Inc. (SCMP) opened at 10.525 on Friday. The firm’s market capitalization is $487.57 million. The firm’s 50-day moving average price is $11.70 and its 200 day moving average price is $10.73. Sucampo Pharmaceuticals, Inc. has a 12 month low of $9.30 and a 12 month high of $17.55.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.06. The company had revenue of $59.90 million for the quarter, compared to analyst estimates of $56.44 million. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. Sucampo Pharmaceuticals’s quarterly revenue was up 15.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.24 earnings per share. Analysts anticipate that Sucampo Pharmaceuticals, Inc. will post $1.01 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/legal-general-group-plc-grows-position-in-sucampo-pharmaceuticals-inc-scmp/1614372.html.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.